Preferred Label : Daratumumab and Hyaluronidase/Dexamethasone/Lenalidomide Regimen;
NCIt synonyms : Lenalidomide/Dexamethasone Plus Darzalex Faspro; Daratumumab and Hyaluronidase-Rd Regimen; Daratumumab Subcutaneous-Lenalidomide-Dexamethasone Regimen; DRD (Daratumumab SC); Darzalex Faspro-Dexamethasone-Lenalidomide; Lenalidomide-Dexamethasone Plus Daratumumab and Hyaluronidase-fihj; Lenalidomide/Dexamethasone Plus Daratumumab and Hyaluronidase Regimen; Daratumumab/Recombinant Human Hyaluronidase/Lenalidomide/Dexamethasone Regimen; Daratumumab and Hyaluronidase-fihj/Lenalidomide/Dexamethasone Regimen; Lenalidomide/Daratumumab and Hyaluronidase-fihj/Dexamethasone Regimen; Daratumumab/Hyaluronidase-Rd Regimen; Darzalex Faspro/Revlimid/Decadron Regimen; Revlimid-Decadron Plus Darzalex Faspro Regimen; Darzalex Faspro/Lenalidomide/Dexamethasone Regimen; Daratumumab and Hyaluronidase-Dexamethasone-Lenalidomide Regimen; Daratumumab and Hyaluronidase/Lenalidomide/Dexamethasone Regimen; Lenalidomide/Daratumumab and Hyaluronidase/Dexamethasone; Daratumumab-Hyaluronidase/Lenalidomide/Dexamethasone; Daratumumab/Hyaluronidase-Lenalidomide-Dexamethasone; Dara-RD (SC Daratumumab); Lenalidomide-Dexamethasone Plus Daratumumab and Hyaluronidase; Daratumumab SC-Rd Regimen; Dara (Daratumumab Subcutaneous)-RD Regimen;
NCIt definition : A regimen consisting of daratumumab and hyaluronidase, dexamethasone and lenalidomide
that is used for the treatment of plasma cell myeloma.;
Codes from synonyms : 28465;
Origin ID : C201879;
chemotherapy_regimen_has_component
- concept_is_in_subset
- regimen_has_accepted_use_for_disease
